Literature DB >> 11255508

Non-redundant tumour supressor functions of transforming growth factor beta in breast cancer.

M Azhar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11255508     DOI： 10.1007/bf02708975

Source DB:  PubMed          Journal:  J Biosci        ISSN： 0250-5991            Impact factor:   1.826


× No keyword cloud information.
  17 in total

Review 1.  Transforming growth factor beta and its receptors: their role in breast cancer.

Authors:  R A Walker
Journal:  Histopathology       Date:  2000-02       Impact factor: 5.087

2.  Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line.

Authors:  H Erbas; L C Lai
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

3.  Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin.

Authors:  M D O'Connor-McCourt; L M Wakefield
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching.

Authors:  H Joseph; A E Gorska; P Sohn; H L Moses; R Serra
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

5.  Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.

Authors:  S J Engle; J B Hoying; G P Boivin; I Ormsby; P S Gartside; T Doetschman
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

6.  Effect of transforming growth factor-beta1 on oestrogen metabolism in MCF-7 and MDA-MB-231 breast cancer cell lines.

Authors:  Y S Ee; L C Lai; K Reimann; P K Lim
Journal:  Oncol Rep       Date:  1999 Jul-Aug       Impact factor: 3.906

7.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

8.  Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.

Authors:  L M Wakefield; J J Letterio; T Chen; D Danielpour; R S Allison; L H Pai; A M Denicoff; M H Noone; K H Cowan; J A O'Shaughnessy
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

9.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes.

Authors:  L P Sanford; I Ormsby; A C Gittenberger-de Groot; H Sariola; R Friedman; G P Boivin; E L Cardell; T Doetschman
Journal:  Development       Date:  1997-07       Impact factor: 6.868

10.  Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development.

Authors:  S D Robinson; G B Silberstein; A B Roberts; K C Flanders; C W Daniel
Journal:  Development       Date:  1991-11       Impact factor: 6.868
View more
  2 in total

1.  G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30.

Authors:  Yu Liu; Fei-Ya Du; Wei Chen; Pei-Fen Fu; Min-Ya Yao; Shu-Sen Zheng
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

Review 2.  Novel RING E3 ubiquitin ligases in breast cancer.

Authors:  Angelika Burger; Yutaka Amemiya; Richard Kitching; Arun K Seth
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.